A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors (NCT05872295)
IKS014-01 IKSUDA
This trial is No longer recruiting
Registration number NCT05872295
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Malaka Ameratunga
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR